BlackRock Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

BlackRock Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2K	Hold	18	–	–	﹤0.01%	3681
2016 Q3	$2K	Hold	18	–	–	﹤0.01%	3687
2016 Q2	$2K	Hold	18	–	–	﹤0.01%	3722
2016 Q1	$1K	Sell	18 -4	-18%	-$309	﹤0.01%	3748
2015 Q4	$3K	Buy	22 +4	+22%	+$2.64K	﹤0.01%	3763
2015 Q3	$13K	Buy	18 +6	+50%	+$6.44K	﹤0.01%	3614
2015 Q2	$10K	Buy	+12	New	+$7.7K	﹤0.01%	3616

Other funds holding EVFM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WAS

WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock Advisors's EVFM Position: Q4 2016 in Review

BlackRock Advisors held its Evofem Biosciences, Inc. Common Stock (EVFM) position steady in Q4 2016 at 18 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

BlackRock Advisors first reported a position in EVFM in Q2 2015 and has held it in 7 quarters since. The position peaked at $13K in Q3 2015. 14 funds tracked by Wall St. Rank hold EVFM as of Q4 2016.

BlackRock Advisors held 18 shares of Evofem Biosciences, Inc. Common Stock worth $2K as of Q4 2016.
BlackRock Advisors left its Evofem Biosciences, Inc. Common Stock share count unchanged in Q4 2016.
Evofem Biosciences, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3681 holding.
BlackRock Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $13K in Q3 2015.
14 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.